When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.

Where is Madrigal Pharmaceuticals located?

Madrigal Pharmaceuticals is headquartered in Conshohocken, United States. It is registered at West Conshohocken, Pennsylvania.

How many employees does Madrigal Pharmaceuticals have?

As of Jun 30, 2026, the latest employee count at Madrigal Pharmaceuticals is 1189.

Is Madrigal Pharmaceuticals a funded company?

Madrigal Pharmaceuticals is a funded company, having raised a total of $38.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 27, 2016.

When was the latest funding round of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' latest funding was a $***** Series A round on Jun 30, 2017, with participation from 0 investor.

What is the annual revenue of Madrigal Pharmaceuticals?

Annual revenue of Madrigal Pharmaceuticals is between $500M and $1B as on Dec 31, 2025

Where does Madrigal Pharmaceuticals rank among its competitors?

Madrigal Pharmaceuticals ranks 3rd amongst 129 active competitors, of which 43 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' top competitors include Nimbus Therapeutics, Intercept Pharmaceuticals and Mammoth. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

Madrigal Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Website: madrigalpharma.com
Email ID: *****@madrigalpharma.com
Registered Address: West Conshohocken, Pennsylvania

Key Metrics

Founded Year

2011

Location

Conshohocken, United States

Stage

Acquired

Total Funding

$38.4M in 2 rounds

Latest Funding Round

Series A, Jun 30, 2017, $*****

Investors

HarbourVest Partners & 4 more

Ranked

3^rd among 129 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

1,189 as on Jun 30, 2026

Similar Companies

Nimbus Therapeutics & 144 more

Exit Details

Acquired by Synta Pharmaceuticals (Apr 14, 2016)

View Madrigal Pharmaceuticals' full profile

Madrigal Pharmaceuticals is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MADRIGAL PHARMACEAUTICALS INC CIN: 453050834 , United States, Active		-	56 (As on Dec 31, 2021)	-
Madrigal Pharmaceuticals, Inc. CIN: 43508648 , United States, Active	Dec 31, 1999	$100M - $500M (As on Dec 31, 2024)	544 (As on Dec 31, 2024)	-
Madrigal Pharmaceuticals Inc CIN: 453050834 , United States, Active	Dec 31, 1999	-	-	-
Madrigal Pharmaceuticals, Inc. CIN: 6756016 , United States, Active	Mar 03, 2023	$500M - $1B (As on Dec 31, 2025)	-	-

Madrigal Pharmaceuticals got acquired by Synta Pharmaceuticals on Apr 14, 2016.

Click here to take a look at Madrigal Pharmaceuticals's acquisition in detail

Madrigal Pharmaceuticals has raised a total funding of $38.4M over 2 rounds. Its first funding round was on Apr 27, 2016. Madrigal Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Madrigal Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2017	4150517	Series A	3130539	2391348	5532295	4280021
Apr 27, 2016	6973133	Series A	2766002	1416475	5869196	3017506

Access funding benchmarks and valuations. Sign up today!

View details of Madrigal Pharmaceuticals's funding rounds and investors

Madrigal Pharmaceuticals' employee count trend

Madrigal Pharmaceuticals has 1,189 employees as of Jun 26. Here is Madrigal Pharmaceuticals's employee count trend over the years:

Employee count trend for Madrigal Pharmaceuticals

Uncover Madrigal Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Madrigal Pharmaceuticals include Nimbus Therapeutics, Intercept Pharmaceuticals and Mammoth. Here is the list of Top 10 competitors of Madrigal Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	67/100
3rd	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	HarbourVest Partners, Avoro Capital & 3 others	66/100
4th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
5th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Deerfield & 9 others	64/100
6th	Drug Farm 2015, Shanghai (China), Series C	Developer of a novel treatment for metabolic diseases	$83M	Zhejiang Private Enterprise United Investment, BioVeda China Fund ... & 7 others	63/100
7th	Ochre Bio 2019, Oxford (United Kingdom), Series A	Developer of ribonucleic acid therapies for treating chronic liver diseases	$39.7M	Khosla Ventures, Y Combinator & 22 others	62/100
8th	Akero Therapeutics 2017, San Francisco (United States), Acquired	Developer of small molecule therapeutics for metabolic disorders	$135M	Janus Henderson Investors, Atlas Venture ... & 12 others	61/100
9th	Altimmune 1997, Gaithersburg (United States), Acquired	Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors	$58M	Gershon Capital, Fidelis Capital & 15 others	61/100
10th	Terns Pharmaceutical 2017, San Mateo (United States), Acquired	Developer of therapies for treating liver disease and cancer	$208M	Lilly Asia Ventures, Deerfield & 6 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Madrigal Pharmaceuticals's competitors? Click here to see the top ones

Madrigal Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Madrigal Pharmaceuticals's geography:

Free

US Tech Semi Annual Funding Report

Edition: H1, 2026 (47 Pages)

View all reports related to Madrigal Pharmaceuticals

Media has covered Madrigal Pharmaceuticals for a total of 40 events in the last 1 year, 28 of them have been about company updates and 2 about partnerships.